TrialReader


Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis

NCT06213909 — Unknown, 318 participants, Xijing Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Retrospective Study of the Effects of Different Pathologic Phenotypes of Bullous Pemphigoid on Clinical Management and Prognosis

RegistryNCT06213909, acronym BP
StatusUnknown
Study typeObservational
Enrollment318 (Estimated)
SponsorXijing Hospital (Other)
ConditionsBullous Pemphigoid
InterventionsThis is a retrospective analysis of health data from inpatient record, no intervention was designed (Other)
Datesstart 2024-01-11 (estimated), primary completion 2024-06-30 (estimated), completion 2024-06-30 (estimated), first posted 2024-01-19, last updated 2024-01-19
Locations1 site in China

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Bullous Pemphigoid All trials of This is a retrospective analysis of health data from inpatient record, no intervention was designed

-Summary

Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity. Various inflammatory cells such as eosinophils, lymphocytes, neutrophils and their granulopoiesis play an important role in the pathogenesis of BP. Infiltration of peripheral blood eosinophils, lymphocytes, and neutrophils into the skin is considered a major feature of BP, making it a heterogeneous disease with different histologic and clinical subtypes. This clinical study was conducted to further investigate the impact of different pathologic phenotypes of BP on the treatment and prognosis of the disease. A retrospective epidemiologic investigative approach was used,and case collection included demographic information, medical history, clinical manifestations, and histopathologic features. Including gender, age, duration of disease, number of days of hospitalization, mucosal involvement, clinical diagnosis before admission, histopathological diagnosis, laboratory tests, concomitant diseases, treatment and its changes in laboratory indexes before and after treatment.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
eosinophil groupOther: This is a retrospective analysis of health data from inpatient record, no intervention was designedBased on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly eosinophils
neutrophil groupOther: This is a retrospective analysis of health data from inpatient record, no intervention was designedBased on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly neutrophil
lymphocyte groupOther: This is a retrospective analysis of health data from inpatient record, no intervention was designedBased on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly lymphocyte
  • This is a retrospective analysis of health data from inpatient record, no intervention was designed (Other): This is a retrospective analysis of health data from inpatient record, no intervention was designed

+Outcome measures

Primary outcomes

  • Bullous Pemphigoid Disease Area Index (BPDAI) severity score [10 years]: We use BPDAI severity score as measure tool

+Eligibility

Sex: All, ages: 0 Years to 100 Years

Inclusion Criteria:

* (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department of Dermatology of Xijing Hospital
* (2) Age 0-100 years old, gender is not limited.
* (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/or anti-BP180 antibody tests.
* (4) Complete skin histopathology information

Exclusion Criteria:

* (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital.
* (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, or other drug therapy within the past month.

+Locations (1)

FacilityCityCountryStatus
Xijing HospitalXi'an, ShaanxiChinaRecruiting

+Investigators

  • Gang Wang, Phd, Principal investigator, Dermatology Department of Xijing Hospital

My Notes